Status:
COMPLETED
Ondansetron Reduce Vomiting Associated With Ketamine PSA
Lead Sponsor:
University of Colorado, Denver
Conditions:
Conscious Sedation
Eligibility:
All Genders
1-21 years
Phase:
NA
Brief Summary
Ondansetron, a commonly used anti-vomiting medication, may reduce the occurrence of vomiting associated with ketamine during procedural sedation in the pediatric emergency department.
Eligibility Criteria
Inclusion
- age 1-21 years, ASA I or II, fracture of dislocation reduction
Exclusion
- age \< 1 year, ASA III or IV, hypertension, glaucoma, acute globe injury, increased intracranial pressure or central nervous system mass lesion, major psychiatric disorder, porphyria, previous adverse reaction to ketamine or ondansetron, parent, guardian or patient unwilling to provide informed consent.
Key Trial Info
Start Date :
December 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2006
Estimated Enrollment :
268 Patients enrolled
Trial Details
Trial ID
NCT00387556
Start Date
December 1 2002
End Date
December 1 2006
Last Update
May 13 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Childrens Hospital
Denver, Colorado, United States, 80218